Conditions: Glaucoma Ocular Hypertension
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 130
Healthy volunteers: no

Brief summary:
The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.

Detailed description:

Arms:
arm 1: Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period.

Interventions: intervention 1: Latanoprostene bunod
Intervention descriptions: intervention 1: None

Protocol document: